Longeveron Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
– Expects to enroll first patient in Phase 2 clinical trial of Lomecel-B™ for Aging-Related Frailty in Japan in 1Q23 – – Extended cash runway into 2H24 – .
06.01.2023 - – Expects to enroll first patient in Phase 2 clinical trial of Lomecel-B for Aging-Related Frailty in Japan in 1Q23 – – Extended cash runway into 2H24 – MIAMI, Jan. 06, 2023 (GLOBE NEWSWIRE) - Longeveron Inc. (NASDAQ: LGVN) ( Longeveron or .
UPDATE -- Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Longeveron Inc Provides Corporate Update and Reports Third Quarter 2022 Financial Results streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.